Search
Supernus Pharmaceuticals Inc
SUPNAdd to Watchlist
43.390USD
-0.360-0.82%
Close 09-23 16:00（ET）
2.52BMarket Cap
LossP/E TTM
About Supernus Pharmaceuticals Inc Company
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Supernus Pharmaceuticals Inc Profile
Ticker SymbolSUPN
Company nameSupernus Pharmaceuticals Inc
IPO dateDec 28, 2010
CEOKhattar (Jack A)
Number of employees674
Security typeOrdinary Share
Fiscal year-endDec 28
Address9715 Key West Avenue
CityROCKVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20850
Phone13018382500
Websitehttps://www.supernus.com
Ticker SymbolSUPN
IPO dateDec 28, 2010
CEOKhattar (Jack A)
Company Executives of Supernus Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.22M
--
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.22M
--
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
60.41K
--
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
60.41K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
27.28K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
27.28K
--
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
27.05K
--
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
27.05K
--
Mr. Frank Mottola
Mr. Frank Mottola
Senior Vice President, Chief Technical Operations Officer
Senior Vice President, Chief Technical Operations Officer
19.54K
--
Mr. Frank Mottola
Mr. Frank Mottola
Senior Vice President, Chief Technical Operations Officer
Senior Vice President, Chief Technical Operations Officer
19.54K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.22M
--
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.22M
--
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
60.41K
--
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
60.41K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
27.28K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
27.28K
--
FAQs
Who are the top five shareholders of Supernus Pharmaceuticals Inc?
The top five shareholders of Supernus Pharmaceuticals Inc are: Mr. Jack A. Khattar
How many institutions hold shares of Supernus Pharmaceuticals Inc (SUPN)?
As of 2026Q1, 651 institutions hold shares of Supernus Pharmaceuticals Inc, with a combined market value of approximately 66.06M, accounting for 113.82% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 238896.00.
What is the biggest source of revenue for Supernus Pharmaceuticals Inc?
In 2026Q1, the Net product sales-Qelbree business generated the highest revenue for Supernus Pharmaceuticals Inc, amounting to 89.24M and accounting for 40.74% of total revenue.